ArticlePharmaceutical research2026
Development and Optimization of Sorafenib Nanosuspension By High-pressure Homogenization for Improved Oral Bioavailability.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeSorafenib (SRF) is a multi-kinase inhibitor approved for the treatment of hepatocellular, advanced renal cell, and differentiated thyroid carcinomas. However, oral bioavailability of SRF is excessively low and variable due to its poor aqueous solubility. Herein, we developed and optimized sorafenib nanosuspensions (SRF-NS) by using different hydrophilic polymers and surfactants for improving its dissolution and oral bioavailability.
methodsSRF-NS were prepared by high-pressure homogenization technique, and were optimized by varying the type and ratio of stabilizers and surfactants, and pressure and number of homogenization cycles. SRF-NS with optimal physicochemical properties were further characterized for surface morphology, physical stability, crystallinity, in vitro dissolution, and in vivo pharmacokinetics.
resultsSRF-NS with SRF/hydroxypropyl cellulose EXF/Tween 80/sodium lauryl sulfate at weight ratios of 10/5/2/1 showed the smallest particle size (~ 328 nm) and low polydispersity index (< 0.3). The optimized SRF-NS exhibited significantly improved dissolution in simulated gastric fluid and simulated intestinal fluid compared with bulk SRF powder. Furthermore, SRF-NS displayed enhanced oral bioavailability in rats with 1.54- and 1.63-times higher C
conclusionNS with reduced particle size and increased solubility could be a promising formulation for enhancing oral bioavailability of SRF.
Indexed as
Identifiers
42736470What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.